PD1-CD19-CART in Patients With r/r B-cell Lymphoma

Inclusion Criteria: 1. Have the capacity to give informed consent; 2. ALL patients with the age between 18 and 70 years old; 3. Expected survival \>3 moths; 4. With no severe heart and lung disease; 5. Previously confirmed diagnosis as CD19+ NHL within 6 months; 6. Hematological index as following, white blood cell (WBC)≥1.5×10\^9/L，absolute neutrophil count (ANC) ≥0.8×10\^9/L, Platelet count≥50×109/L, Hemoglobin (Hgb) ≥ 90mg/L, lymphocyte count≥ 0.4×10\^9/L； 7. Blood biochemical index as no more than 1.5\* ULN, including total bilirubin (TBIL), transglutaminase (AST), alanine aminotransferase (AST), Creatinine (SCr), Urea in patients with no tumor metastasis in liver and kidney; Blood biochemical index no more than 5\* ULN in patients with tumor metastasis in liver and kidney; 8. With a stable cardiac function, the left ventricular ejection fraction (LVEF) ≥ 55%; 9. Virological tests were negative for EBV, CMV, HIV, TP and HCV; a negative HBV DNA test is acceptable if HBsAg is positive; 10. ECOG \<2; 11. Relapsed or refractory (r/r) NHL including, Diffuse large B cell lymphoma(DLBCL, NOS), stage Ⅲ-Ⅳ;Primary mediastinal large B-cell lymphoma (PMBL), stage Ⅲ-Ⅳ; High grade B-cell lymphoma (HGBL), stage Ⅲ-Ⅳ; Mantle cell lymphoma (MCL), stage Ⅲ-Ⅳ; follicular lymphoma (FL), stage Ⅲ-Ⅳ and with aggression. r/r NHL defined as following, demonstrate disease that persists or relapse after achieving complete response (CR) after \> 2 cycles of standard chemotherapy, or relapse after autologous hematopoietic stem cell transplantation (auto-HSCT), or not achieving CR after auto-HSCT. Exclusion Criteria: 1. Pregnant or lactating women; 2. With a pregnancy plan in the next 2 years; 3. Prior treatment of anti-GVHD therapy; 4. Acceptance of allogeneic stem cell transplant (ASCT); 5. Isolated extramedullary relapse of ALL; 6. Severe mental disorders, active autoimmune diseases, active infectious diseases, severe cardiovascular diseases; 7. Partial prothrombin time or activated partial thromboplastin time or international standardized ratio \> 1.5\*ULN without anticoagulant treatment; 8. History of other type of maligant tumors; 9. Any circumstances that possibly increase the risk of subjects or interfere with study results, which judged by investigator.